Loading...
XASX
ATH
Market cap42bUSD
Jul 15, Last price  
0.01AUD
1D
0.00%
1Q
33.33%
Jan 2017
-73.91%
IPO
-98.69%
Name

Alterity Therapeutics Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
27.25
EPS
—
Div Yield, %
—
Shrs. gr., 5y
413.07%
Rev. gr., 5y
105.93%
Revenues
4m
+2.63%
2,642,335762,486507,044491,997428,193215,008156,135186,664150,867363,775176,842142,657132,396201,174108,538411,5673,254,0483,537,3683,916,3334,019,285
Net income
-19m
L+38.51%
0000-7,522,789-4,906,922-6,431,185-5,239,469-7,787,242-13,329,239-5,885,069-7,729,551-7,542,076-8,265,737-12,337,830-10,059,684-15,309,353-12,847,061-13,806,515-19,123,464
CFO
-13m
L-37.08%
0000-6,994,174-4,708,939-4,558,415-6,845,906-7,951,254-13,788,974-10,871,074-7,418,526-5,865,080-6,245,188-13,954,818-9,431,122-17,330,069-12,337,274-20,035,837-12,605,824

Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
URL
https://alteritytherapeutics.com/
IPO date
Mar 28, 2000
Employees
11
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
4,019
2.63%
3,916
10.71%
Cost of revenue
23,621
18,523
Unusual Expense (Income)
NOPBT
(19,602)
(14,607)
NOPBT Margin
Operating Taxes
46
104
Tax Rate
NOPAT
(19,648)
(14,711)
Net income
(19,123)
38.51%
(13,807)
7.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,145
317
BB yield
Debt
Debt current
107
107
Long-term debt
211
206
Deferred revenue
Other long-term liabilities
20
Net debt
(12,321)
(15,460)
Cash flow
Cash from operating activities
(12,606)
(20,036)
CAPEX
(6)
(7)
Cash from investing activities
(6)
(36)
Cash from financing activities
9,216
124
FCF
(13,578)
(21,322)
Balance
Cash
12,639
15,774
Long term investments
Excess cash
12,438
15,578
Stockholders' equity
13,798
22,813
Invested Capital
1,519
7,572
ROIC
ROCE
EV
Common stock shares outstanding
3,648,876
4,046
Price
Market cap
EV
EBITDA
(19,454)
(14,504)
EV/EBITDA
Interest
Interest/NOPBT